

# Male Hypogonadism

Joe Canales, MD  
Endocrinology, Diabetes and Metabolism  
Kaiser Permanente, San Diego

---

---

---

---

---

---

---

---

## Overview

- Evaluation of Male Hypogonadism
- Management of Male Hypogonadism
- Risks With Hormone Therapy
- Cases
- Monitoring on Hormone Therapy
- Gynecomastia

---

---

---

---

---

---

---

---

[www.swiftypoll.com](http://www.swiftypoll.com)

Swiftypoll.com

Enter Poll Passcode: 73048

Submit

---

---

---

---


---

---

---

---

# Hypothalamic Pituitary Function




---

---

---

---


---

---

---

---

## HYPOTHALAMIC-PITUITARY-GONADAL AXIS




---

---

---

---


---

---

---

---

## HYPOTHALAMIC-PITUITARY-GONADAL AXIS



SHBG = Sex Hormone Binding Globulin

---

---

---

---

---

---

---

---

## Conditions Causing Low SHBG

### Conditions that are associated with decreased SHBG concentrations

- Obesity
- Diabetes mellitus
- Use of glucocorticoids, some progestins, and androgenic steroids
- Nephrotic syndrome
- Hypothyroidism
- Acromegaly
- Polymorphisms in the SHBG gene

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al. JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

---

---

## Conditions Causing High SHBG

### Conditions associated with increased SHBG concentrations

- Aging
- HIV disease
- Cirrhosis and hepatitis
- Hyperthyroidism
- Use of some anticonvulsants
- Use of estrogens
- Polymorphisms in the SHBG gene

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al. JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---


---

---

---

---

## Testosterone and Aging



CellCode.com

---

---

---

---

---

---


---

---

---

---

## Testosterone: Diurnal Variation



urologycentre.com

---

---

---

---

---

---

---

---

## Signs and Symptoms of Hypogonadism

- Changes in mood (fatigue, depression, anger)
- Decreased body hair (feminization)
- Decreased bone mineral density
- Decreased lean body mass and muscle strength
- Decreased libido and erectile quality and frequency
- Increased visceral fat
- Hot Flashes/Sweats
- Oligospermia or azospermia.
- Gynecomastia
- Decreased testicular volume

---

---

---

---

---

---

---

---

## Non Specific Symptoms

### Nonspecific symptoms and signs associated with testosterone deficiency

- Decreased energy, motivation, initiative, and self-confidence
- Feeling sad or blue, depressed mood, persistent low-grade depressive disorder
- Poor concentration and memory
- Sleep disturbance, increased sleepiness
- Mild unexplained anemia (normochromic, normocytic)
- Reduced muscle bulk and strength
- Increased body fat, body mass index

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al., JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

## The ADAM Questionnaire

1. Do you have a decrease in libido (sex drive)?
2. Do you have a lack of energy?
3. Do you have a decrease in strength and/or endurance?
4. Have you lost height?
5. Have you noticed a decreased "enjoyment of life?"
6. Are you sad and/or grumpy?
7. Are your erections less strong?
8. Have you noticed a recent deterioration in your ability to play sports?
9. Are you falling asleep after dinner?
10. Has there been a recent deterioration in your work performance?

If you answered YES to questions 1 or 7 or any 3 other questions, you may have low testosterone.

\*\*Adapted from Morley JE, et al. Validation of a screening questionnaire for androgen deficiency in aging males. *Metabolism*. 2000;49(9):1259-1262.

---

---

---

---

---

---

---

---

---

---

---

---

## Causes of Low T

### ■ Common Causes

- Obesity (negative estrogen feedback)
- Aging
- Medications (narcotics, glucocorticoids)
- Previous exogenous use of Testosterone
- "Nutritional supplements"
- HIV (hypothalamic, testicular, malnutrition, medications, glucocorticoids)

### ■ Less common Causes

- Nutritional (anorexia)
- Previous trauma, infections, undescended testis
- Klinefelter's syndrome
- Kallman's syndrome
- Autoimmune Testicular dysfunction

---

---

---

---

---

---

---

---

---

---

---

---

## Evaluation of Hypogonadism

- Morning Testosterone level (before 0900)
- Repeat morning Testosterone level
  - Low T considered below lower limit or Free T measurement below normal
- LH, FSH, Prolactin, Estradiol, SHBG, cbc
- Karyotype (small testicular volume, high LH and FSH)
- MRI sella (low LH and FSH)?

---

---

---

---

---

---

---

---


---

---

---

---

## Evaluation of Low T



Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al, JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

---

---

## Treatment Guidelines: Who To Treat?

- Only men with symptoms and signs consistent with testosterone (T) deficiency
- And unequivocally and consistently low serum T concentrations or low free testosterone on repeated testing
- Men who have had proper initial evaluation for cause of low T

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al, JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

---

---

## Treatment Guidelines: Who Not to Treat

- Patients planning fertility in the near term
- History of breast or prostate cancer
- A palpable prostate nodule or induration
- PSA level > 4 ng/mL, PSA > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation
- Elevated hematocrit
- Untreated severe obstructive sleep apnea
- Severe lower urinary tract symptoms
- Uncontrolled heart failure
- MI or stroke within the last 6 months
- Thrombophilia

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al, JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

---

---

## Treatment Guidelines: Prostate

- In men 50-69 and have a life expectancy > 10 yrs
  - Discuss risks and benefits of prostate cancer monitoring
  - Engage the patient in “shared decision making”
  - For patients who choose prostate monitoring
    - Baseline evaluation (DRE, PSA)
    - Evaluation 3-12 months after starting T
- In men 40 to 69 years old and at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer)
  - discuss prostate cancer risk with the patient and offer monitoring options

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al. JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

---

---

## Treatment Guidelines: Older men with age-related decline in testosterone concentration

- Andropause
  - Age related testicular and pituitary dysfunction
- Endocrine Society does not recommend therapy for age related decline in T
- In men >65 years who have symptoms or conditions suggestive of testosterone deficiency (such as low libido or unexplained anemia) and consistently and unequivocally low morning testosterone concentration:
  - Offer testosterone therapy on an individualized basis after explicit discussion of the potential risks and benefits

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al. JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

---

---

## Testosterone Therapies

Depo Testosterone Enanthate or Cypionate	50-100mg IM Weekly 100-200mg IM q 2 wks
Testosterone Gel 1% or 1.6%	5-10gm daily to skin (non -genital)
Testosterone Patch	2-4mg patch, 1-2 nightly, back, thigh or upper arm
Buccal Mucosa Testosterone	30 mg of a bioadhesive buccal T tablet to buccal mucosa Q 12 hrs
Testosterone Pellets	Pellets implanted SQ q 3-6 months
Testosterone Solution	60 mg of testosterone (1 pump or 1 twist actuation of 30 mg of testosterone to each axilla) Daily
Intranasal Testosterone	11 mg two or three times daily

---

---

---

---

---

---


---

---

---

---

## Testosterone Injection Pharmacokinetics



Me, J. Canales, MD, May, 2019

---

---

---

---


---

---

---

---

## Testosterone Gel Pharmacokinetics



---

---

---

---

---

---

---

---

## Testosterone Gel: Precautions

- Patients should wash their hands immediately with soap and water application of AndroGel
- Patients should cover the application site(s) with clothing after the gel has dried (e.g. a shirt)
- If another person comes in contact with AndroGel, wash with soap and water immediately
- Changes in body hair distribution, significant increase in acne or other signs of virilization of the female partner should be brought to the attention of the provider.

<https://www.accessdata.fda.gov/>

---

---

---

---

---

---

---

---



## Testosterone Gel: Contact Exposure

- Clinical Study: men and their female partners
  - 2-12 hours after application of gel
  - Male and female partners engaged in 15 minutes of “vigorous skin to skin contact”
- Results
  - Female partners had a >2 fold increase in serum testosterone levels above baseline
  - When a shirt was used by the male partner, no increase in testosterone was seen in the female partner

<https://www.accessdata.fda.gov>

---

---

---

---


---

---

---

---

## Testosterone Patch



Androderm.com

---

---

---

---

---

---

---

---

[www.swiftypoll.com](http://www.swiftypoll.com)

Swiftypoll.com

Enter Poll Passcode:

---

---

---

---

---

---

---

---

## Testosterone Benefits

- Improvement in bone mineral density
  - No data for fracture reduction
- Sexual Function
  - Improved libido, erectile function, and sexual activity
  - Does not improve ejaculatory function
- Mood
  - Improvement in general mood
  - No improvement in depressive symptoms
- Increases fat free mass and muscle strength
  - Reduces whole body, intraabdominal, and intermuscular fat

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al., JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---

---

---

---

## Testosterone Side Effects

- Prostate hypertrophy (elevation in PSA)
- Erythrocytosis
- Increased sleep apnea risk/severity
- Acne/Oily Skin
- **Impaired fertility**
- Water retention
- Gynecomastia
- Potential for partner contact (gel)
- Stimulation of prostate cancer already present
- Increased cardiovascular risk?
  - Older men > 60 or 65, with pre-existing CAD or high risk

---

---

---

---

---

---

---

---

## Testosterone: CVD Risk

- There have been no RCTs that were large enough or long enough to determine the effects of T-replacement therapy on major adverse cardiovascular events (MACE)
- No conclusive evidence that T supplementation is associated with increased cardiovascular risk in hypogonadal men
- FDA Announcement 3/3/15
  - Required manufacturers to add information to the labeling about a possible increased risk of heart attacks and strokes in patients taking testosterone

---

---

---

---

---

---

---

---

## Testosterone Monitoring

- Therapy should aim to raise serum T concentrations into the mid-normal range
- Evaluate patient 3-6 months after starting
- Monitor T levels in 3-6 months
  - Injections: If mid-interval T is >600 ng/dL (24.5 nmol/L) or <350 ng/dL (14.1 nmol/L), adjust dose or frequency
  - Transdermal gels: assess T concentrations 2–8 h following the gel application, after the patient has been on treatment for at least 1 wk
  - Transdermal patches: assess T concentrations 3–12 h after application; adjust dose to achieve T concentration in the mid-normal range.
- CBC baseline then q 3-6 months for first year then yearly

---

---

---

---

---

---

---

---

## Testosterone Therapy: Urology Referral

- Urology Evaluation
  - If in the first 12 months of treatment the PSA increases > 1.4ng/mL above baseline or
  - If the PSA rises above 4.0 ng/mL or
  - If there is abnormality detected on digital rectal exam

Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline  
Shalender Bhasin et al, JCEM Volume 103, Issue 5, May 2018

---

---

---

---

---


---

---

---

## Gynecomastia

- Breast tissue formation with enlargement of the breast and tenderness, often retro-areolar
- Due to Testosterone/Estrogen imbalance



news-medical.net

---

---

---

---

---

---

---

---

## Gynecomastia: Causes

- Low testosterone
  - Aging, Obesity
- Medications
  - Digoxin, Cimetidine, Spironolactone, Luprolide, Narcotics
- Iatrogenic (too much testosterone)
  - Supplement “Boosters”
- Alcohol, Marijuana
- Tumor
  - HCG
  - Estrogen

---

---

---

---

---

---

---

---

## Gynecomastia: Work Up

- Medication List
- Good history
  - Alcohol, marijuana use, weight lifting supplements
- Physical Exam
  - Breast
  - Testis
- Laboratory
  - HCG, morning T, SHBG (T panel), LH, FSH, Estradiol, TSH, prolactin

---

---

---

---

---

---

---

---

## Gynecomastia: Treatment

- Weight loss
- Stop alcohol
- Stop offending medication if possible
- Surgery
- Off label Medications (not FDA approved for this purpose)
  - Tamoxifen 10mg BID
  - Anastrozole 1mg daily

---

---

---

---

---

---

---

---

## Common Pitfalls

- Not checking morning Testosterone
- Not checking free fraction of Testosterone
- Not repeating Testosterone level
- Not obtaining history of supplement use
- Starting Testosterone without appropriate work up... then referring to endocrine.
- Not measuring Testosterone at the correct time when on therapy
- Recommend weight loss for the obese patient first
- Not performing sleep apnea testing for fatigue

---

---

---

---

---

---

---

---

## Conclusions

- Testosterone Physiology
- Evaluation of Hypogonadism
- Management of Hypogonadism
- Risks and Benefits with Testosterone Therapy
- Gynecomastia causes and management

---

---

---

---

---

---

---

---